Switch theme
Sign up to access all valuation multiples
Shinva Medical Instrument Co Ltd manufactures medical instruments in China. Its main products include sterilizers and testing products, radiotherapy and digital diagnosis equipment, surgical instruments and pharmaceutical machinery.
1993
1.4K+
LTM Revenue $1.5B
LTM EBITDA $143M
$1.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Shinva has a last 12-month revenue of $1.5B and a last 12-month EBITDA of $143M.
In the most recent fiscal year, Shinva achieved revenue of $1.4B and an EBITDA of $138M.
Shinva expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Shinva valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $1.4B | $1.4B | XXX | XXX | XXX |
| Gross Profit | $317M | $338M | XXX | XXX | XXX |
| Gross Margin | 23% | 24% | XXX | XXX | XXX |
| EBITDA | $138M | $140M | XXX | XXX | XXX |
| EBITDA Margin | 10% | 10% | XXX | XXX | XXX |
| Net Profit | $76.7M | $69.2M | XXX | XXX | XXX |
| Net Margin | 6% | 5% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Shinva's stock price is CNY 15 (or $2).
Shinva has current market cap of CNY 9.3B (or $1.3B), and EV of CNY 7.9B (or $1.1B).
See Shinva trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.1B | $1.3B | XXX | XXX | XXX | XXX | $0.17 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Shinva has market cap of $1.3B and EV of $1.1B.
Shinva's trades at 0.7x LTM EV/Revenue multiple, and 7.6x LTM EBITDA.
Analysts estimate Shinva's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Shinva and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $1.1B | XXX | XXX | XXX |
| EV/Revenue | 0.8x | XXX | XXX | XXX |
| EV/EBITDA | 7.8x | XXX | XXX | XXX |
| P/E | 12.8x | XXX | XXX | XXX |
| P/E/Growth | 1.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpShinva's NTM/LTM revenue growth is 6%
Shinva's revenue per employee for the last fiscal year averaged $1.0M, while opex per employee averaged $0.2M for the same period.
Over next 12 months, Shinva's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Shinva's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Shinva and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 4% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 10% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 2% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 16% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $1.0M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 4% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 2% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 4% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 19% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Shinva acquired XXX companies to date.
Last acquisition by Shinva was XXXXXXXX, XXXXX XXXXX XXXXXX . Shinva acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Shinva founded? | Shinva was founded in 1993. |
| Where is Shinva headquartered? | Shinva is headquartered in China. |
| How many employees does Shinva have? | As of today, Shinva has 1.4K+ employees. |
| Is Shinva publicy listed? | Yes, Shinva is a public company listed on SHG. |
| What is the stock symbol of Shinva? | Shinva trades under 600587 ticker. |
| When did Shinva go public? | Shinva went public in 2002. |
| Who are competitors of Shinva? | Similar companies to Shinva include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Shinva? | Shinva's current market cap is $1.3B |
| What is the current revenue of Shinva? | Shinva's last 12-month revenue is $1.5B. |
| What is the current EBITDA of Shinva? | Shinva's last 12-month EBITDA is $143M. |
| What is the current EV/Revenue multiple of Shinva? | Current revenue multiple of Shinva is 0.7x. |
| What is the current EV/EBITDA multiple of Shinva? | Current EBITDA multiple of Shinva is 7.6x. |
| What is the current revenue growth of Shinva? | Shinva revenue growth between 2023 and 2024 was 4%. |
| Is Shinva profitable? | Yes, Shinva is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
